Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients.
Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients.
复制标题
DOI：
10.2174/1381612826666201001125604
复制
发表时间：
2021
影响因子：
3.1
通讯作者：
Al-Horani RA
中科院分区：
文献类型：
--
作者：
Aliter KF;Al-Horani RA
新冠肺炎大流行是由冠状病毒引起的，又称严重急性呼吸综合征冠状病毒2型。病毒感染继续影响全球，没有疫苗来预防感染，也没有高效的疗法来治疗世界各地数百万受感染的人。这种疾病最初是一种呼吸道感染，但也可能与高凝状态、过度产生细胞因子导致的严重炎症以及潜在的显著氧化应激有关。这种疾病可能会进展为多器官衰竭，最终导致死亡。在这篇文章中，我们总结了潘生丁作为新冠肺炎辅助治疗的潜力。我们回顾了描述潘生丁在不同测试环境中的生物活性的文献。数据检索自PubMed、SciFinder-CAS和Web of Science。该综述简要介绍了自1977年以来的相关研究。潘生丁是一种被批准的抗血小板药物，已被用于预防中风等适应症。文献表明，除了抗血栓活性外，双嘧达莫还促进许多其他生物活性，包括抗病毒、抗炎和抗氧化活性。潘生丁可能大大有助于改善新冠肺炎治疗的临床结果。药物的药代动力学曲线已经确定，这使得设计适当的治疗过程变得更容易。该药物通常也是安全的、负担得起的，并且在全球范围内都可以买到。初步临床试验显示，双嘧达莫在治疗危重新冠肺炎患者方面有很大的前景，但还需要更大规模的随机对照试验来证实这一前景。
COVID-19 pandemic is caused by coronavirus also known as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The viral infection continues to impact the globe with no vaccine to prevent the infection or highly effective therapeutics to treat the millions of infected people around the world. The disease starts as a respiratory infection, yet it may also be associated with a hypercoagulable state, severe inflammation owing to excessive cytokines production, and a potentially significant oxidative stress. The disease may progress to multiorgan failure and eventually death. In this article, we summarize the potential of dipyridamole as an adjunct therapy for COVID-19. We reviewed the literature describing the biological activities of dipyridamole in various settings of testing. Data were retrieved from PubMed, SciFinder-CAS, and Web of Science. The review concisely covered relevant studies starting from 1977. Dipyridamole is an approved antiplatelet drug, that has been used to prevent stroke, among other indications. Besides its antithrombotic activity, the literature indicates that dipyridamole also promotes a host of other biological activities including antiviral, anti-inflammatory, and antioxidant ones. Dipyridamole may substantially help improve the clinical outcomes of COVID-19 treatment. The pharmacokinetics profile of the drug is well established which makes it easier to design an appropriate therapeutic course. The drug is also generally safe, affordable, and available worldwide. Initial clinical trials have shown a substantial promise for dipyridamole in treating critically ill COVID-19 patients, yet larger randomized and controlled trials are needed to confirm this promise.
登录
查看更多内容
DOI：
10.1111/j.1749-6632.2010.05784.x
发表时间：
2010-01-01
期刊：
INNATE INFLAMMATION AND STROKE
影响因子：
--
作者：
De Caterina, Raffaele;Massaro, Marika;Carluccio, Maria Annunziata
通讯作者：
Carluccio, Maria Annunziata
DOI：
10.1124/jpet.105.089987
发表时间：
2005-11-01
影响因子：
3.5
作者：
Chakrabarti, S;Vitseva, O;Freedman, JE
通讯作者：
Freedman, JE
影响因子：
5
作者：
Chen, Yen-Cheng;Chen, Cheng-Hsien;Chen, Tso-Hsiao
通讯作者：
Chen, Tso-Hsiao
DOI：
10.1016/0306-3623(95)02098-5
发表时间：
1996-07-01
期刊：
GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM
影响因子：
--
作者：
DelaCruz, JP;Olveira, C;delaCuesta, FS
通讯作者：
delaCuesta, FS
影响因子：
4
作者：
Barnes, Geoffrey D.;Burnett, Allison;Minichiello, Tracy
通讯作者：
Minichiello, Tracy